-
2024-517606-29-00
5
2020-10-30
Central retinal artery occlusion
-
2025-522632-14-00
4
2026-05-11
Non-small cell lung cancer (NSCLC)
-
2025-524111-37-00
7
2026-04-28
advanced solid tumors
-
2025-523088-39-00
1
2026-01-28
Advanced Solid Tumors
-
2025-522731-34-00
3
2026-01-23
Ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-519917-72-00
5
2025-10-29
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2025-522774-36-00
1
2025-10-24
Advanced solid tumors
-
2024-519188-17-00
1
2025-10-07
Relapsed/refractory malignancy with documented diagnosis of human epid
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-517190-24-00
4
2025-09-16
Peritoneal Cancer
-
2024-518154-16-00
5
2025-08-27
non-small cell lung cancer
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-513547-82-00
5
2025-03-11
Transthyretin Amyloidosis
-
2023-509632-26-00
9
2025-02-11
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head an
-
2024-516440-25-00
1
2025-02-06
KRAS G12D-mutant solid tumors.
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2023-505242-25-00
4
2024-11-05
High-Risk Monoclonal Gammopathy of Undetermined Significance;
Non-Hig